Phase 2 Brain Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have a confirmed tissue diagnosis of a relapsed or returning brain tumour — specifically glioblastoma multiforme (GBM), anaplastic astrocytoma, fibrillary astrocytoma, pilomyxoid astrocytoma, oligodendroglioma, or anaplastic mixed oligoastrocytoma — or a radiologically diagnosed diffuse intrinsic brainstem glioma (DIPG)
- People who have at least one measurable tumour site that can be monitored during the trial
- People who score at least 60% on a standard medical scale used to measure ability to carry out daily activities (confirm with trial site)
- People who have not received chemotherapy in the three weeks before starting treatment
- People whose blood counts meet minimum levels — specifically, a white blood cell type called neutrophils at or above 1,000/mm³ and platelets at or above 100,000/mm³
- People whose liver and kidney function blood test results fall within acceptable ranges before enrolment
- People whose blood clotting test results fall within acceptable ranges before enrolment
- People who have not received growth factor medications within one week before joining the trial
- People with brain tumours who are taking the steroid dexamethasone, provided the dose has been stable or decreasing for at least one week before joining
- People of reproductive age who agree to use an effective method of contraception during treatment and for three months afterward; women of childbearing age will need to take a pregnancy test before entering the study
- People (or their parents or guardians, where applicable) who are able to understand and sign a written consent form at the time of screening
- People who have had a craniotomy (brain surgery) must have had it more than two weeks before starting the trial's treatment
Who may not be able to join:
- People who are currently pregnant or breastfeeding
- People of childbearing potential — including women and fertile men — who do not agree to use effective contraception during the trial and for three months after treatment ends
- People who have significant other medical or psychiatric conditions that could put them at greater risk or affect their ability to receive or follow through with treatment and follow-up monitoring
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Heather McCrea, MD, University of Miami
Phone: 305-585-3627
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Treatment Related Adverse Events; Composite Overall Response Rate (CORR); Progression-free survival (PFS); Overall Survival (OS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.